Cel-Sci is focused on improving the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. The company’s lead investigational therapy is Multikine, currently being studied in a pivotal global phase 3 clinical trial. CVM is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients, and a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. For more information visit the company’s Web site at www.cel-sci.com
Let us hear your thoughts below: